

# Global Cancer Monoclonal Antibodies Market - 2025

<https://marketpublishers.com/r/GF1803A4044BEN.html>

Date: April 2026

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: GF1803A4044BEN

## Abstracts

The Global Cancer Monoclonal Antibodies Market was valued at USD 66.7 Billion in 2025 and is anticipated to reach by , at a CAGR of 0.095 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Cancer Monoclonal Antibodies Market.

This report delivers a comprehensive overview of the Global Cancer Monoclonal Antibodies Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Cancer Monoclonal Antibodies Market. The Global Cancer Monoclonal Antibodies Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–.

Global Cancer Monoclonal Antibodies Market Scope:

By Monoclonal Antibodies

Humanized

Murine

Chimeric

Human

Rat

Immunotoxin

Immunoadhesin

Others

### By Therapies

Bevacizumab (Avastin)

Rituximab (Rituxan)

Trastuzumab (Herceptin)

Cetuximab (Erbix)

Panitumumab (Vectibix)

Other

### By Applications

Non-small-cell lung cancers

Colorectal Cancer

Breast Cancer

Prostate Cancer

Blood Cancer

Glioma cancers

Bladder Cancer

Lymphoma

Ovarian Cancer

Others

### Key Players

Amgen Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genmab AS

GlaxoSmithKline PLC

Johnson & Johnson

Novartis AG

Merck & Co., Inc

Spectrum Pharmaceuticals Inc.(LIST NOT EXHAUSTIVE)

### Major Highlights

This report delivers a comprehensive overview of the Global Cancer Monoclonal Antibodies Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in

the current market, and make informed business decisions regarding Global Cancer Monoclonal Antibodies Market. The Global Cancer Monoclonal Antibodies Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

#### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

#### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

## Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. MARKET DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Market Snippet by Type
- 3.2. Market snippet By Therapies
- 3.3. Market snippet By Applications
- 3.4. Market Snippet by Region

### **4. MARKET DYNAMICS**

- 4.1. Market Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Growing Prevalence of Cancer
    - 4.1.1.2. Increasing Investment in Research and Development of Genomic Studies
  - 4.1.2. Restraints:
    - 4.1.2.1. Stringent Regulatory Guidelines
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Regulatory Analysis

### **6. BY MONOCLONAL ANTIBODIES**

- 6.1. Introduction
  - 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Monoclonal Antibodies Segment
  - 6.1.2. Market Attractiveness Index, By Monoclonal Antibodies Segment

## 6.2. Humanized\*

### 6.2.1. Introduction

6.2.2. Market Size Analysis, US\$ Million, 2026-2033 and Y-o-Y Growth Analysis (%), 2021-2029

## 6.3. Murine

## 6.4. Chimeric

## 6.5. Human

## 6.6. Rat

## 6.7. Immunotoxin

## 6.8. Immunoadhesin

## 6.9. Others

## 7. BY THERAPIES

### 7.1. Introduction

7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapies

7.1.2. Market Attractiveness Index, By Therapies

### 7.2. Bevacizumab (Avastin)\*

#### 7.2.1. Introduction

7.2.2. Market Size Analysis, US\$ Million, 2026-2033 and Y-o-Y Growth Analysis (%), 2021-2029

### 7.3. Rituximab (Rituxan)

### 7.4. Trastuzumab (Herceptin)

### 7.5. Cetuximab (Erbix)

### 7.6. Panitumumab (Vectibix)

### 7.7. Other

## 8. BY APPLICATIONS

### 8.1. Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Applications

8.1.2. Market Attractiveness Index, By Sample Segment

### 8.2. Non-small-cell lung cancers\*

#### 8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2026-2033 and Y-o-Y Growth Analysis (%), 2021-2029

### 8.4. Colorectal Cancer

### 8.5. Breast Cancer

### 8.6. Prostate Cancer

- 8.7. Blood Cancer
- 8.8. Glioma cancers
- 8.9. Bladder Cancer
- 8.10. Lymphoma
- 8.11. Ovarian Cancer
- 8.12. Others

## **9. BY REGION**

### 9.1. Introduction

9.1.1. Market Size Analysis, US\$ Million, 2026-2033 and Y-o-Y Growth Analysis (%), 2021-2029, By Region

9.1.2. Market Attractiveness Index, By Region

### 9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Monoclonal Antibodies

9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapies

9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Applications

9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

### 9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Monoclonal Antibodies

9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapies

9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Applications

9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. U.K.

9.3.6.3. France

9.3.6.4. Italy

9.3.6.5. Spain

9.3.6.6. Rest of Europe

### 9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Monoclonal Antibodies

9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapies

9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Applications

9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Monoclonal Antibodies

9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapies

9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Applications

9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. Australia

9.5.6.5. Rest of Asia Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Monoclonal Antibodies

9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapies

9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Applications

## **10. COMPETITIVE LANDSCAPE**

10.1. Key Developments and Strategies

10.2. Company Share Analysis

10.3. Product Benchmarking

10.4. Key Companies to Watch

## **11. COMPANY PROFILES**

11.1. Amgen Inc.\*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. Bristol Myers Squibb Company

11.3. Eli Lilly and Company

11.4. F. Hoffmann-La Roche Ltd

11.5. Genmab AS

11.6. GlaxoSmithKline PLC

11.7. Johnson & Johnson

11.8. Novartis AG

11.9. Merck & Co., Inc

11.10. Spectrum Pharmaceuticals Inc. (\*LIST NOT EXHAUSTIVE)

## **12. DATAM INTELLIGENCE**

12.1. Appendix

12.2. About Us and Services

12.3. Contact Us

## I would like to order

Product name: Global Cancer Monoclonal Antibodies Market - 2025

Product link: <https://marketpublishers.com/r/GF1803A4044BEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF1803A4044BEN.html>